Morgan Stanley Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target upped by Morgan Stanley from $225.00 to $226.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC raised their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a report on Monday, January 12th. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Finally, Piper Sandler reissued an “overweight” rating and issued a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $212.86.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $196.83 on Wednesday. The business has a fifty day moving average of $168.72 and a 200-day moving average of $150.60. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $197.47. The firm has a market cap of $11.96 billion, a PE ratio of -32.97, a price-to-earnings-growth ratio of 0.93 and a beta of 0.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 7.03%. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the company earned $6.51 EPS. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. On average, equities research analysts predict that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the sale, the senior vice president directly owned 19,508 shares in the company, valued at $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the transaction, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JAZZ. Kennedy Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $1,100,000. Essex Investment Management Co. LLC acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $2,697,000. Wedge Capital Management L L P NC acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at $27,834,000. Sequoia Financial Advisors LLC bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at about $605,000. Finally, Aberdeen Group plc bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $8,629,000. 89.14% of the stock is currently owned by institutional investors.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — Jazz posted $6.64 EPS and $1.20B revenue, topping consensus and showing y/y revenue growth; investors view the print as confirmation of underlying demand. Earnings Call Summary
• Positive Sentiment: Company issued 2026 revenue guidance of $4.25B–$4.50B, in line with/near street expectations, reducing near‑term forecasting uncertainty and supporting the rally. Press Release
• Positive Sentiment: Strong product performance — Xywav ($1.7B, 12% y/y) and Epidiolex ($1.1B, 9% y/y) drove growth; Modeyso had a strong early launch ($37M in its first full quarter), supporting the top‑line beat. Product Sales Detail
• Positive Sentiment: Multiple analyst price‑target upgrades and bullish notes hit after the results (Bank of America to $275, Wells Fargo to $250, Morgan Stanley to $226, RBC to $195), amplifying buying interest from institutions and momentum traders. Analyst Upgrades
• Positive Sentiment: Pipeline progress: company expects to complete an sBLA submission for zanidatamab under RTOR in 1Q26 for HER2+ first‑line GEA — a successful filing/approval could materially expand oncology revenue over time. Pipeline & Guidance
• Neutral Sentiment: Management released the earnings slide deck and full call transcript — useful for digging into margin drivers, product cadence and assumptions behind 2026 guidance. Earnings Transcript
• Negative Sentiment: Profitability nuance: the company still showed a negative net margin in the quarter (impacted by non‑operating items and costs), so investors should watch whether earnings quality improves as 2026 progresses. Earnings Metrics
• Negative Sentiment: Valuation and risk: JAZZ trades at a relatively elevated P/E and carries leverage (debt/equity ~1.1); while analysts raised targets, some (RBC) show limited near‑term upside versus the current price — consider valuation vs. growth when sizing positions. Analyst Context

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.